IV Ketamine Therapy

What Is IV Ketamine Therapy?

IV Ketamine therapy involves the administration of sub-anesthetic doses of ketamine through an intravenous infusion to treat psychiatric conditions including treatment-resistant depression, post-traumatic stress disorder, anxiety disorders, obsessive-compulsive disorder, and chronic pain syndromes. At RECO Integrated Psychiatry, our board-certified psychiatrists administer ketamine infusions in a carefully monitored clinical setting designed for patient safety and comfort.

Ketamine was first synthesized in 1962 and approved by the FDA as an anesthetic in 1970. It has been used safely in operating rooms and emergency departments for over five decades. In the early 2000s, landmark research at Yale University and the National Institute of Mental Health demonstrated that sub-anesthetic doses of ketamine produced rapid and robust antidepressant effects, even in patients who had not responded to multiple traditional antidepressant medications.

Since those initial discoveries, hundreds of clinical studies have confirmed ketamine's antidepressant properties, establishing it as one of the most significant psychiatric treatment advances of the 21st century. While IV ketamine is used off-label for psychiatric conditions (meaning the FDA has not specifically approved it for depression), off-label use is a common and well-accepted medical practice supported by substantial clinical evidence.

The use of IV ketamine for psychiatric conditions is supported by the American Psychiatric Association, which published a consensus statement acknowledging the growing evidence base for ketamine therapy and providing clinical guidance for its administration. At RECO Integrated Psychiatry, we follow evidence-based protocols that align with expert consensus guidelines to ensure optimal outcomes and patient safety.

The Science Behind Ketamine: Glutamate and Neuroplasticity

Understanding how ketamine works in the brain helps explain both its rapid onset of action and its potential for producing lasting changes in mood and cognition. The mechanism is fundamentally different from traditional antidepressants and involves several interconnected molecular pathways.

NMDA Receptor Antagonism

Ketamine's primary pharmacological action is as an antagonist at the N-methyl-D-aspartate (NMDA) receptor, a type of ionotropic glutamate receptor widely distributed throughout the brain. Glutamate is the brain's primary excitatory neurotransmitter, involved in virtually every cognitive function including learning, memory, and mood regulation. In depression, the glutamate system is often dysregulated, leading to impaired communication between neurons and weakened synaptic connections.

By blocking NMDA receptors on GABAergic interneurons, ketamine paradoxically increases glutamate release in certain brain regions, particularly the prefrontal cortex. This surge of glutamate activates a different type of glutamate receptor called the AMPA receptor, triggering a cascade of intracellular signaling events that ultimately promote neuroplasticity.

BDNF and Synaptogenesis

The activation of AMPA receptors stimulates the release of brain-derived neurotrophic factor (BDNF), a protein that acts as a powerful growth factor for neurons. BDNF activates the mTOR (mechanistic target of rapamycin) signaling pathway, which promotes the synthesis of synaptic proteins necessary for the formation of new dendritic spines and synaptic connections.

In animal studies, a single sub-anesthetic dose of ketamine was shown to increase the number of dendritic spines in the prefrontal cortex within 24 hours, effectively reversing the synaptic damage caused by chronic stress. This process of rapid synaptogenesis, the creation of new synaptic connections, is believed to be the structural basis for ketamine's fast-acting antidepressant effects.

Additional Mechanisms

Beyond NMDA antagonism, ketamine also interacts with opioid receptors, sigma receptors, monoamine transporters, and voltage-gated calcium and sodium channels. It has anti-inflammatory properties and may reduce neuroinflammation, which is increasingly recognized as a contributor to depression and other psychiatric conditions. These multiple mechanisms of action may explain why ketamine is effective for a broader range of conditions than traditional antidepressants.

Treatment Protocol: Six Infusions Over Two to Three Weeks

The standard IV ketamine protocol for psychiatric conditions consists of a series of six infusions administered over a period of two to three weeks. This schedule has been established through clinical research and real-world clinical experience as the approach most likely to produce sustained improvement.

IV Ketamine vs. Spravato: Understanding the Differences

Both IV ketamine and Spravato (esketamine) target the glutamate system and can produce rapid antidepressant effects, but they differ in several important ways. The following comparison can help you understand which option may be more appropriate for your situation.

Feature	IV Ketamine	Spravato (Esketamine)
Active Compound	Racemic ketamine (S + R enantiomers)	Esketamine (S-enantiomer only)
Administration Route	Intravenous infusion	Nasal spray
FDA Approval Status	Off-label for psychiatric use (FDA-approved as anesthetic)	FDA-approved for TRD and MDD with suicidal ideation
Session Duration	~40 min infusion + 1-2 hr recovery	~10 min administration + 2 hr monitoring
Treatment Schedule	6 infusions over 2-3 weeks, then maintenance	Twice weekly x 4 wks, then weekly, then biweekly
Dosing Flexibility	Highly customizable (dose, rate, duration)	Fixed doses (56 mg or 84 mg)
Insurance Coverage	Generally not covered; self-pay	Covered by most major insurers
Conditions Treated	Depression, PTSD, anxiety, OCD, chronic pain	Treatment-resistant depression, MDD with suicidal ideation
Response Rate	~60-70% for depression	~50-70% for depression

Who Is a Candidate for IV Ketamine?

IV ketamine therapy may be appropriate for adults who meet certain clinical criteria. During your initial consultation, your psychiatrist will assess your candidacy based on your diagnosis, treatment history, and overall health.

You may be a candidate for IV ketamine if you:

• Have been diagnosed with major depressive disorder and have not responded adequately to two or more antidepressant medications
• Are experiencing PTSD symptoms that have not resolved with first-line treatments such as psychotherapy and SSRIs
• Suffer from severe anxiety disorders that are significantly impacting your quality of life despite conventional treatment
• Have OCD that has been resistant to standard pharmacological and behavioral interventions
• Are experiencing active suicidal ideation and need rapid relief while longer-acting treatments take effect
• Have chronic pain conditions (such as CRPS, fibromyalgia, or neuropathic pain) that co-occur with psychiatric symptoms

IV ketamine may not be appropriate for individuals with uncontrolled hypertension, active psychotic disorders, a history of ketamine or PCP misuse, pregnancy, or certain cardiovascular conditions. A thorough medical screening is performed before any infusion.

Conditions Treated with IV Ketamine

The clinical evidence base for IV ketamine spans multiple psychiatric and pain conditions. At RECO Integrated Psychiatry, we treat the following conditions with IV ketamine therapy:

• Treatment-Resistant Depression: The condition with the largest body of evidence supporting ketamine therapy. Multiple randomized controlled trials demonstrate rapid and significant improvement in depressive symptoms.
• Suicidal Ideation: Ketamine has shown remarkable ability to rapidly reduce suicidal thoughts, often within hours of a single infusion. This anti-suicidal effect appears to be independent of its antidepressant action.
• Post-Traumatic Stress Disorder: Emerging evidence supports ketamine's efficacy for PTSD, with studies showing significant reductions in intrusive memories, avoidance, and hyperarousal symptoms.
• Anxiety Disorders: Studies demonstrate that ketamine can produce rapid anxiolytic effects in generalized anxiety disorder and social anxiety disorder.
• Obsessive-Compulsive Disorder: Research indicates that ketamine may rapidly reduce obsessive thoughts and compulsive behaviors in patients with treatment-resistant OCD.
• Chronic Pain Syndromes: Low-dose ketamine infusions are effective for neuropathic pain, complex regional pain syndrome (CRPS), fibromyalgia, and other chronic pain conditions, particularly when they co-occur with depression.

What to Expect During IV Ketamine Treatment

Before Your Infusion

Fast for at least four to six hours before your appointment (clear liquids are acceptable up to two hours before). Take your regular medications unless instructed otherwise by your psychiatrist. Arrange for a responsible adult to drive you home after the session. Wear comfortable clothing and bring anything that helps you relax, such as headphones, an eye mask, or a light blanket.

During the Infusion

You will be seated in a comfortable reclining chair in a private, dimly lit treatment room. A nurse will place a small IV catheter in your arm or hand and attach monitoring equipment to track your heart rate, blood pressure, and oxygen levels throughout the session. The ketamine infusion is delivered slowly over approximately 40 minutes at a dose carefully calibrated by your psychiatrist.

During the infusion, you will likely experience altered perceptions, including a sense of floating or disconnection from your body, changes in visual and auditory perception, and an altered sense of time. Most patients describe the experience as dreamlike and relaxing. Our clinical team remains with you throughout the entire infusion to ensure your comfort and safety.

After the Infusion

The acute effects of the ketamine infusion typically resolve within 30 to 60 minutes after the infusion ends. You will remain in our recovery area until our clinical team determines you are ready to leave, usually about one to two hours after the infusion is complete. You may feel tired, slightly disoriented, or emotionally heightened for the remainder of the day. Most patients feel significantly better the next morning. You must not drive, operate machinery, or make important decisions until the following day.

Side Effects and Safety Considerations

IV ketamine at sub-anesthetic doses has a well-established safety profile when administered under medical supervision. The most common side effects are transient and resolve during or shortly after the infusion.

Common Side Effects

• Dissociation: A feeling of disconnection from one's body or surroundings, which is dose-dependent and typically resolves within an hour after the infusion ends.
• Nausea: Occurs in approximately 10-15% of patients and can be managed with pre-treatment anti-nausea medication.
• Elevated blood pressure: Transient increases in blood pressure and heart rate are common and are monitored throughout the session.
• Dizziness and drowsiness: Lightheadedness and fatigue that typically resolve during the recovery period.
• Perceptual changes: Altered visual, auditory, or tactile perceptions that are generally mild and transient at therapeutic doses.
• Headache: Mild headache that may occur after the infusion and responds to standard analgesics.

Safety Protocols

At RECO Integrated Psychiatry, every ketamine infusion is administered under the direct supervision of medical professionals. Continuous monitoring of vital signs, oxygen saturation, and cardiac rhythm ensures that any adverse reactions are detected and managed immediately. We maintain full resuscitation equipment and emergency medications on-site at all times.

Cost and Insurance Information

Because IV ketamine therapy for psychiatric conditions is considered off-label, it is generally not covered by health insurance plans. However, some plans may provide partial coverage for the office visit and monitoring components. Patients should check with their individual insurance carrier for specific coverage details.

Frequently Asked Questions